Biogen Idec Management Discusses Q3 2012 Results - Earnings Call Transcript Seeking Alpha In a second latebreaking presentation at ECTRIMS, we highlighted primary efficacy results from SELECTION, the one-year extension study of SELECT, the first registrational study of daclizumab HYP or DAC. The results of SELECTION supported the positive ... Biogen Idec Increases Revenue 6 percent to $1.4 Billion in the Third Quarter |
